A fatal case of cabozantinib-induced cardiomyopathy.
Future Cardiol
; : 1-5, 2024 Aug 05.
Article
in En
| MEDLINE
| ID: mdl-39101435
ABSTRACT
Cabozantinib, a multi-kinase receptor inhibitor, is utilized in the treatment of advanced malignancies such as metastatic renal cancers. While rare, cabozantinib-induced cardiotoxicity has emerged as a recognized adverse effect with potentially reversible outcomes. We report the case of a 55-year-old male who developed fatal cardiomyopathy 4 months after initiating cabozantinib therapy. Despite its rarity, cardiomyopathy after initiation of cabozantinib can be lethal if not diagnosed early. This case underscores a significant gap in the surveillance of patients treated with newer agents like cabozantinib. Larger observational studies are needed to assess the prevalence and impact of cardiomyopathy after initiation of cabozantinib therapy, and to determine the cost-effectiveness of early surveillance protocols.
[Box see text].
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Future Cardiol
Journal subject:
CARDIOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
United States